Teacher Retirement System of Texas Increases Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Teacher Retirement System of Texas increased its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 18.4% during the 4th quarter, Holdings Channel reports. The firm owned 16,263 shares of the company’s stock after acquiring an additional 2,532 shares during the quarter. Teacher Retirement System of Texas’ holdings in Nurix Therapeutics were worth $306,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Intech Investment Management LLC bought a new position in Nurix Therapeutics during the 3rd quarter worth about $425,000. The Manufacturers Life Insurance Company boosted its stake in shares of Nurix Therapeutics by 32.4% during the third quarter. The Manufacturers Life Insurance Company now owns 30,383 shares of the company’s stock valued at $683,000 after purchasing an additional 7,441 shares in the last quarter. FMR LLC increased its holdings in Nurix Therapeutics by 675.9% during the third quarter. FMR LLC now owns 586,902 shares of the company’s stock valued at $13,188,000 after buying an additional 511,256 shares during the period. Cinctive Capital Management LP bought a new position in Nurix Therapeutics in the third quarter worth approximately $2,364,000. Finally, Patient Square Capital LP purchased a new stake in Nurix Therapeutics during the third quarter worth $7,320,000.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on NRIX shares. Royal Bank of Canada lifted their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. HC Wainwright lifted their target price on Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Leerink Partnrs upgraded shares of Nurix Therapeutics to a “hold” rating in a report on Monday, March 17th. Stephens reissued an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Finally, Morgan Stanley lifted their price objective on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a research report on Monday, February 3rd. Three equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, Nurix Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $30.88.

Insider Activity

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the sale, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. The trade was a 6.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Houte Hans Van sold 2,811 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the sale, the chief financial officer now directly owns 39,549 shares in the company, valued at $785,047.65. This trade represents a 6.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,326 shares of company stock valued at $213,449. Company insiders own 7.20% of the company’s stock.

Nurix Therapeutics Trading Down 11.9 %

Shares of Nurix Therapeutics stock opened at $10.47 on Wednesday. The firm’s 50 day simple moving average is $16.01 and its two-hundred day simple moving average is $20.16. The firm has a market capitalization of $794.54 million, a price-to-earnings ratio of -3.62 and a beta of 2.18. Nurix Therapeutics, Inc. has a 12-month low of $10.37 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. On average, sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.